Eledon Pharmaceuticals, Inc. (ELDN) Form 8-K — May 13, 2026
Eledon Pharmaceuticals, Inc. reported its first quarter 2026 financial results, including a net loss of $39.0 million, or $0.33 per basic common share. This compares to a net loss of $6.5 million, or $0.08 per basic common share, in the same period of 2025. The net loss in the first quarter of 2026 included a non-cash loss of $19.0 million from changes in the fair value of warrant liabilities.
Key figures
- Eps
- -0.33
- Eps Beat
- 0
- Revenue
- 0
- Guidance
- Current cash, cash equivalents and short-term investments to fund operations into 2Q 2027
- Net Income
- -39,025
- Total Debt
- 46,209
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 146,667
- Cash Position
- 111,100
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 112,424,211
- E GFR 12 months
- 67.0
- E GFR 24 months
- 74.2
- Insulin independence patients
- 10
- Insulin independence total patients
- 12
Price after filing
1 day: +1.8%7 days: -1.0%30 days: -8.0%
Close on the filing date to close N calendar days later (from $3.88). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.